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The Targeted SMAC Mimetic SW IV-134 is a
strong enhancer of standard chemotherapy
in pancreatic cancer
Yassar M. Hashim1,7, Suwanna Vangveravong2, Narendra V. Sankpal1, Pratibha S. Binder3, Jingxia Liu1,4,
S. Peter Goedegebuure1,5, Robert H. Mach6, Dirk Spitzer1,5 and William G. Hawkins1,5*

Abstract
Background: Pancreatic cancer is a lethal malignancy that frequently acquires resistance to conventional
chemotherapies often associated with overexpression of inhibitors of apoptosis proteins (IAPs). We have recently
described a novel means to deliver second mitochondria-derived activator of caspases (SMAC) mimetics selectively to
cancer cells employing the sigma-2 ligand/receptor interaction. The intrinsic death pathway agonist SMAC offers an
excellent opportunity to counteract the anti-apoptotic activity of IAPs. SMAC mimetics have been used to sensitize
several cancer types to chemotherapeutic agents but cancer-selective delivery and appropriate cellular localization
have not yet been considered. In our current study, we tested the ability of the sigma-2/SMAC drug conjugate
SW IV-134 to sensitize pancreatic cancer cells to gemcitabine.
Methods: Using the targeted SMAC mimetic SW IV-134, inhibition of the X-linked inhibitor of apoptosis proteins
(XIAP) was induced pharmacologically and its impact on cell viability was studied alone and in combination with
gemcitabine. Pathway analyses were performed by assessing caspase activation, PARP cleavage and membrane
blebbing (Annexin-V), key components of apoptotic cell death. Single-agent treatment regimens were compared
with combination therapy in a preclinical mouse model of pancreatic cancer.
Results: The sensitizing effect of XIAP interference toward gemcitabine was confirmed via pharmacological
intervention using our recently designed, targeted SMAC mimetic SW IV-134 across a wide range of commonly
used pancreatic cancer cell lines at concentrations where the individual drugs showed only minimal activity. On
a mechanistic level, we identified involvement of key components of the apoptosis machinery during cell death
execution. Furthermore, combination therapy proved superior in decreasing the tumor burden and extending
the lives of the animals in a preclinical mouse model of pancreatic cancer.
Conclusion: We believe that the strong sensitizing capacity of SW IV-134 in combination with clinically relevant
doses of gemcitabine represents a promising treatment option that warrants clinical evaluation.
Keywords: Sigma-2 receptors, Sigma-2/SMAC drug conjugate, Gemcitabine, Combination therapy, Pancreatic cancer
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Background
Pancreatic cancer is one of the most aggressive malignancies with an estimated 53,070 new cases and 41,780
deaths in the United States in 2016, with a 5-year survival rate of only 8% (Ref. [1]). Surgical intervention remains the only potential cure and even after surgery, the
5-year survival rate is only 10 - 25 percent due to the
high rates of local recurrence and metastases [2]. Gemcitabine is a recommended treatment for pancreatic cancer and is used to treat both localized and metastatic
disease. Gemcitabine can also be used in combination
with radiation therapy [3]. Unfortunately, the benefits of
gemcitabine therapy and other chemotherapies are rather limited. For example, gemcitabine chemotherapy
only modestly improved overall survival to 6.8 months
in patients with stage IV disease [4]. The response rate
by Response Evaluation Criteria in Solid Tumors
(RECIST criteria) for first line gemcitabine is only 9.4%
[4]. A comparison between a combination of multiple active components such as FOLFIRINOX (5-FU, Irinotecan,
Leucovorin and Oxaliplatin), versus a mix of Gemzar and
albumin-complexed paclitaxel (Abraxane), did show similar disease control but both regimens were associated with
substantial off-side toxicities [5]. Outcomes like these
highlight the urgent need to develop more effective treatment options for patients with pancreatic cancer.
Pancreatic cancers use several mechanisms to evade
apoptosis as they acquire resistance to conventional
chemotherapy [6]. The inhibitor of apoptosis proteins
(IAP) frequently contribute to drug resistance via blockade of caspase activation [7]. More specifically, the Xlinked inhibitor of apoptosis proteins (XIAP) is a wellcharacterized member of the IAP family. It contains
baculovirus IAP repeat (BIR) domains, of which BIR-2 is
involved in blocking caspases-3/7 while BIR-3 interferes
with activation of caspase-9 [8–10]. High intracellular
XIAP levels have been attributed to chemoresistance in
many pancreatic cancer cell lines as well as primary tumors [11]. Second mitochondria-derived activator of
caspases (SMAC) is a mitochondrial protein that is released into the cytosol when cells are exposed to stress,
and amplifies the apoptotic pathway by inhibiting IAP
activity [12]. SMAC competitively binds to the caspasebinding domains of XIAP, resulting in their activation
[12, 13]. Several SMAC mimetics have been described as
potential therapeutics for cancer therapy and as sensitizers for traditional chemotherapeutics [14–17].
We have previously shown that sigma-2 receptors are
overexpressed in human pancreatic cancer cells [18]. We
have also demonstrated that sigma-2 ligands can enter
and deliver additional drug cargos into pancreatic cancer
cells [19]. We have recently described the novel drug
conjugate SW IV-134, composed of the SMAC mimetic
SW IV-52 and the sigma-2 ligand SW43 [20]. This
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potent cancer drug selectively targets the cancer cells via
binding to the overexpressed sigma-2 receptor and induces cell death by delivering the SMAC mimetic SW
IV-52 [20]. SW IV-134 has a high cytotoxic activity in
the low micromolar range on pancreatic cancer cells in
vitro and in mouse models of pancreatic cancer [20].
A key limitation of conventional chemotherapy is the
toxicity to normal tissues due to a lack of selective cancer
cell delivery. The purpose of this study was to evaluate the
therapeutic potential of combining a targeted SMAC
mimetic (SW IV-134) with gemcitabine in an effort to improve the efficacy of the non-targeted chemotherapeutic.

Methods
Compounds

The synthesis of SW IV-134 was performed in our
laboratory and has been previously described [20].
Gemcitabine (Gemzar®) was purchased from Eli Lilly
(Indianapolis, IN).
Cell lines

PANC-1, CFPAC-1, BxPC-3, AsPC-1, and MIA PaCa-2
were obtained from American Type Culture Collection
(ATCC, Manassas, VA). CFPAC-1 was cultured in Iscove’s
modified medium with 4 mM L-glutamine, 1.5 g/L
Sodium bicarbonate, and 10% fetal bovine serum (FBS).
MIA PaCa-2 was cultured in Dulbecco's Modified Eagle's
medium with 10% FBS and 2.5% horse serum. BxPC-3
and AsPC-1 were cultured in RPMI- 1640 medium with
10% FBS. Antibiotics, penicillin (100 μg/mL) and streptomycin (100 μg/mL) were added to the media. Cells
were maintained in a humidified incubator at 37 °C
with 5% CO2.
Evaluation of cytotoxicity in vitro

Cells were plated at a density of 1 × 104/well in 96-well
plates for 24 hours prior to treatment. SW IV-134 was
dissolved in DMSO and diluted in culture medium to
achieve a final concentration of 1 μM (the DMSO concentration was always kept below 1% and had thus no
impact on the experimental results). Gemcitabine was
dissolved in PBS to achieve a concentration of 0.5 μM.
Cells were treated with the SW IV-134, gemcitabine, and
combination of both drugs that contained 1 μM of SW
IV-134 and 0.5 μM of gemcitabine. Cell viability was determined 3 - 4 days after treatment using CellTiter-Glo
Luminescent Viability Assay (Promega, Madison, WI).
Luminescence signal was measured using a multi-mode
microplate reader (Bio-Tek, Winooski, VT). All assays
were performed in triplicates.
Lentivirus mediated XIAP knockdown

The lentiviral constructs, pLKO.1 for XIAP (sh-1,
TRCN0000003785; sh-2, TRCN0000003787) and Luciferase
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(sh-Luc) were obtained from Washington University
genome center. shRNA constructs were transfected into
HEK293T cells together with the lentiviral packaging
plasmids VSVG (envelope) and Δ8.9 (gag, pol), using
Fugene 6 (Roche, Indianapolis, IN). Viral supernatants
were collected at 48 and 72 hours and added to PANC-1
and MIA PaCa-2 cells in the presence of protamine sulfate
(10 μg/mL). Infected cells were selected with Puromycin
(2 μg/mL). The drug selection process was monitored via
GFP fluorescence (as part of the lentiviral vectors) and
was in the range of 90% positive cells.

Immunoblotting

Cells were lysed in radioimmunoprecipitation assay
buffer [50 mM Tris, 150 mM sodium chloride, 1 mM
EDTA, 1% Nonidet P40, and 0.25% SDS (pH 7.0)].
The buffer was supplemented with complete protease
inhibitor cocktail (Roche, Mannheim, Germany). Protein concentration was measured by BCA protein
assay kit (Thermo Fisher Scientific, Rockford, IL).
Samples containing equal amounts of protein were
run on NuPAGE Bis-Tris 4 - 12% gradient gels and
then transferred onto PVDF membranes (Life Technologies, Grand Island, NY). The membranes were incubated in blocking buffer (5% dry milk) for 1 hour,
followed by addition of the respective primary antibodies at 4 °C overnight. The following day,
membranes were washed with TBS-T and incubated
with HRP-conjugated secondary antibodies at room
temperature for 1 hour. SuperSignal West Dura Substrate (Thermo Fisher Scientific Rockford, IL) was
used to detect the secondary antibodies. Primary and
secondary antibodies for capase-3, cleaved caspase-3,
Poly ADP-ribose polymerases (PARP), cleaved PARP,
and XIAP were purchased from Cell Signaling Technology
(Danvers, MA). Primary and secondary actin antibodies
were purchased from Santa Cruz (Dallas, TX). Antibody
dilutions were made according to the manufacturer’s
instructions.

In vitro evaluation of apoptosis (Annexin-V staining)

AsPC-1 cells were seeded in 6-well plates at a density
of 5 × 105/well for 24 hours. Cells were treated for 48
hours with 0.5 μM of SW IV-134, 0.5 μM of gemcitabine, equimolar concentration of both drugs, and
DMSO as a control. Apoptosis was detected using
Annexin-V FITC Kit (Biolegend, San Diego, CA). Propidium iodide was added to differentiate early apoptotic
cells from necrotic and late stage apoptotic cells. Cells
were prepared according to the manufacturer's instructions and analyzed with a FACSCalibur flow cytometer
(BD Biosciences, San Jose, CA).
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In vitro caspase activation assays

Caspase-3, 8 and 9 activities were measured in PANC-1
and AsPC-1 cells using Caspase-Glo Assay Systems
(Promega, Madison, WI) according to the manufacturer’s instructions. This assay is based on luminogenic
caspase substrates which are cleaved by activated caspases resulting in generation of a luminescence signal.
Cells were seeded at a density of 1 × 104 in 96-well
plates for 24 hours. Then, they were treated for 48 hours
with 1 μM of SW IV-134, 0.5 μM of gemcitabine, combination of the two drugs, and DMSO as a control. The
contents of the plate were mixed using an orbital shaker
for 30 seconds and incubated at room temperature for
90 minutes. Luminescence signal was measured using a
multi-mode microplate reader (Bio-Tek, Winooski, VT).
In vivo assessment of tumor growth, survival, and toxicity

Immunocompromised female nude mice (6 weeks old,
Harlan Laboratories, Indianapolis, IN) were injected
in the right flank with 200 μL single cell suspension of
1 × 106 AsPC-1 cells in RPMI medium. Treatment
started when tumors reached approximately 5 mm in
diameter. Mice were randomized into four groups (n = 14).
The groups received daily i.p. injections with 100 μL of vehicle (25% cremophor in H2O), weekly gemcitabine (3 mg),
daily SW IV-134 (750 nmoles) with and without weekly
gemcitabine (3 mg). Tumors were measured every other
day with a digital caliper and the volumes were calculated
using the equation V = d1 (d2)2/2, (V = volume, d1 = larger
diameter, d2 = smaller diameter). Following conclusion of
treatment at day 21, five mice from each group were sent
to the Division of Comparative Medicine at our institution
for toxicity evaluation. Blood was collected for complete
blood count (CBC) and biochemical analysis (AST, ALT,
BUN, total bilirubin, and Cr). Organs were examined
grossly and histologically. Mice were euthanized when
tumors reached a diameter of 2 cm or ulcerated. Animal
euthanasia was performed using a carbon-dioxide (CO2)
chamber. Mice were placed in the CO2 chamber (≤10 mice
at a time) and 100% CO2 was introduced at a slow rate,
replacing 30% of the chamber volume in 1 minute. Mice
were exposed to CO2 for five minutes followed by a two
minute dwell period. Animal studies were carried out in
accordance with the Washington University Division of
Comparative Medicine guidelines for care and use of
laboratory animals. The protocol was approved by the
Animal Studies Committee of Washington University
(protocol 20130073).
Statistics

Statistical analyses and data plotting were performed using
GraphPad Prism software version 5 (San Diego, CA).
Results were expressed as mean ± SEM of at least 3 biological replicates. One-way ANOVA was used to analyze
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the differences in viability and caspase activity assays. Unpaired two tailed t-tests were used to evaluate the difference in CBC, biochemistry analyses, viability of knockdown cells, and to confirm the difference in subgroups.
Two-way ANOVA was used to analyze the difference in
tumor sizes. Kaplan-Meier survival analysis was used and
the difference between the groups was compared with a
log-rank test. A p-value < 0.05 was considered significant
for all analyses.

Results
Low XIAP expression sensitizes pancreatic cancer cells to
gemcitabine

XIAP has been shown to be involved in resistance of pancreatic cancer to conventional chemotherapy [11, 21]. In
order to compensate the anti-apoptotic properties of this
molecule, much higher doses of, e.g. gemcitabine might be
required to achieve an adequate treatment benefit. High
doses of chemotherapy are almost inevitably correlated
with substantial side effects for the patients. In order to
verify that low XIAP expression increases the sensitivity
of pancreatic cancer cells to gemcitabine, we genetically
decreased the expression level of XIAP using shRNA.
The pancreatic cancer cell lines PANC-1 and MIA
PaCa-2 were stably infected with two lentiviral shRNA
clones directed against human XIAP. Cells infected
with luciferase-specific shRNA were used as controls.
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Western blot analysis confirmed reduced XIAP expression levels for both cell lines (Fig. 1a and b). To assess
the impact of reduced XIAP expression levels on gemcitabine sensitivity, the cells were treated with gemcitabine for 4 days. While the controls did not show any
signs of cell death induction, the viability of XIAPdepleted cells was reduced to ~60% (Fig. 1c, d, e and f ).
Of note, we have previously shown the effect of SW IV134 on functional blockage of XIAP and rapid degradation of cIAP-1/2, which leads to NIK-dependent TNFα
production and augmented target cell apoptosis [20, 22].
These data confirm published reports about the important role of XIAP in the chemoresistance of pancreatic cancer cells to gemcitabine and validate the
experimental model used to assess our tumor-targeted
SMAC mimetics.
SW IV-134 sensitizes pancreatic cancer to gemcitabine

Since the SMAC moiety of our cancer-targeted small
molecule drug conjugate SW IV-134 displaces XIAP
from its designated caspases (3/7 and 9), leading to their
activation [23, 24], we hypothesized that SW IV-134
would also improve the sensitivity of pancreatic cancer
cells to gemcitabine, known to develop resistance against
this chemotherapeutic [25, 26]. Pancreatic cancer cells
were thus treated with our targeted SMAC mimetic to
explore if the cells could be rendered sensitive to

Fig. 1 Down regulation of XIAP expression sensitizes pancreatic cancer cells to gemcitabine. a PANC-1 and b MIA PaCa-2 cells were infected with
lentiviral vectors encoding two XIAP-specific shRNAs (sh-1 and sh-2) and a luciferase-specific control (sh-Luc). Stable cell pools were generated using
puromycin drug selection. XIAP knockdown was confirmed by Western blot analysis and resulted in expression levels of 49% - 37% (PANC-1,
sh-1, sh-2) and 42% - 28% (MIA PaCa-2, sh-1, sh-2), respectively, with the sh-2 clone being slightly more potent in both cell lines. The cells
were treated with low-dose gemcitabine (0.5 μM) and the viability was assessed 4 days later. While treatment of the sh-Luc controls did not
induce cell death, the percentage of live cells after treatment with gemcitabine decreased by ~40% for both cell lines and both XIAP shRNA
clones. c and d, PANC-1, ***p < 0.001 and **p < 0.01. e and f, MIA PaCa-2, *p < 0.05 (n = 3)
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gemcitabine pharmacologically. We chose to treat all cell
lines with sublethal concentrations of the respective drugs.
For example, the IC50 data for SW IV-134 were already
established in our previous report and ranged from 6.3 to
9.2 μM [20]. We used this information as a guide and selected a 1 μM concentration of SW IV-134 for all experiments. The sublethal concentration for gemcitabine was
identified in a pilot study (see also Fig. 1c, d, e and f). At
the selected doses, single-agent treatment with SW IV134 or gemcitabine showed minimal reduction in cell viability (Fig. 2, 73% - 85% and 80% - 100%, respectively).
In contrast, the combination of the two drugs substantially decreased the cell viability to as low as ~15%
(Fig. 2e, p < 0.001 for all analyses). The effects of the
drugs, when used in combination, were much greater
than the sum of the individual reagents, suggesting a
synergistic effect (Fig. 2).
SW IV-134 augments gemcitabine-induced activation of
both the intrinsic and the extrinsic pathways of apoptosis

Both SW IV-134 and gemcitabine are capable of inducing cell death via apoptosis [20, 27]. Since combination
of the two compounds correlated with enhanced killing
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profiles using sublethal concentrations of the individual
components, we asked if these effects were a consequence of augmented apoptosis induction. Cleaved
caspase-3 (the major executioner caspase of apoptosis)
and cleaved PARP (a major sensor of DNA damage and
cell stress) were used to monitor pathway induction via
Western blotting [28, 29]. PANC-1 cells were treated in
vitro with gemcitabine, in the absence or presence of
SW IV-134. Following treatment, cell lysates were prepared and submitted to Western blot analysis. Low-dose
SW IV-134 alone was unable to produce either activated
caspase-3 or PARP, while low-dose gemcitabine resulted
in limited generation of the two apoptosis indicators.
Only the two drugs combined produced a substantial increase in signal intensities for the activated apoptosis
markers caspase-3 and PARP, respectively (Fig. 3a).
For further assessment of apoptosis involvement
during combination treatment, AsPC-1 cells were exposed to SW IV-134 and gemcitabine alone, an equimolar mix of the drugs and DMSO (control). The cells
were subsequently assessed for membrane blebbing
(Annexin-V) and PI uptake. The combination of both
drugs resulted in the highest degree of early apoptosis

Fig. 2 SW IV-134 sensitizes pancreatic cancer cells to gemcitabine. a BxPC-3, b AsPC-1, c CFPAC-1, d MIA PaCa-2, and e PANC-1 cells were treated
with SW IV-134 (1 μM), gemcitabine (0.5 μM), or in combination with the two drugs using the same concentrations. Titer-Glo viability assays were
performed after 3 - 4 days post treatment (MIA PaCa-2, 4 days; all other cell lines, 3 days). The data were normalized to DMSO treated control cells
(***p < 0.001) (n = 3)
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Fig. 3 SW IV-134 augments gemcitabine-induce apoptotic cell death. a PANC-1 cells were treated with DMSO (control), SW IV -134 (1 μM), gemcitabine
(0.5 μM), and a combination of the two drugs at their respective concentrations. Apoptotic cell death was assessed by Western blot analysis via monitoring
the activation status of caspase-3 and PARP 48 hours after treatment. Beta-Actin was used a loading control. b A complementary flow cytometry-based
assay was employed to assess apoptotic cell death via Annexin-V/PI staining. AsPC-1 cells were treated essentially as in (a) but SW IV-134 was (0.5 μM). After
two days, the cells were submitted to Annexin-V/PI staining. Shown are representative FACS dot plots for the indicated treatment conditions
(n = 4). DMSO-treated cells served as a control. The Annexin-V+/PI- cells in the lower right quadrant represent early apoptotic cells

with 34% of cells being Annexin-V+/PI– (Fig. 3b). Only
gemcitabine single-agent treatment resulted in a somewhat elevated level of early apoptosis (5.5%), while none
of the other groups showed clear evidence of treatment
effects (DMSO and SW IV-134 with 0.9% and 1.3%, respectively). These data further suggest that low-dose
combination therapy mediates strong cytotoxicity in an
apoptosis-dependent fashion.
Endogenous SMAC competitively displaces XIAP from
the BIR-3 binding groove that mediates caspase-9 interaction, leading to its activation [8]. We have previously
shown that SW IV-134 is capable of inducing caspase-9
cleavage (intrinsic death pathway), which mimics the activity of the native SMAC molecule [20]. SW IV-134 also
induces NF-κB-mediated, TNFα-dependent extrinsic
pathway activation via degradation of cellular inhibitor
of apoptosis proteins-1 (cIAP-1) [20, 22]. Gemcitabine
has been shown to activate caspases 8 and 9 [27]. To
evaluate the relative contribution of these two pathways
in apoptosis following combination treatment, the

activation status of caspases 3, 8, and 9 was monitored
in PANC-1 and AsPC-1 cells. In PANC-1, treatment with
the individual drugs increased all caspase levels ~1.7 - fold
above baseline, while the combination of both drugs led
to a ~2.4 - fold increase (+41%, Fig. 4a, p < 0.01). While
treatment of AsPC-1cells with individual drugs increased
all caspase levels ~1.3-fold above baseline, the combination of both drugs relative to SW IV-134 treatment led
to an ~3-fold increase in caspase-3 activity, the executioner caspase of programmed cell death (+130%, Fig. 4b,
p < 0.01). These results are consistent with our cytotoxicity
data and suggest that both pathways of apoptosis are activated much more efficiently when gemcitabine is combined with SW IV-134.
SW IV-134 enhances gemcitabine therapy in a preclinical
xenograft model of pancreatic cancer

In an attempt to verify our in vitro findings in an appropriate animal model of pancreatic cancer, we inoculated
AsPC-1 cells into the flanks of female nude mice
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Fig. 4 SW IV-134 induces both intrinsic and extrinsic pathways of apoptosis. a PANC-1 and b AsPC-1 cells were treated with SW IV-134 (1 μM),
gemcitabine (0.5 μM), and a combination of the two drugs at their respective concentrations. The activation status of caspases 3, 8 and 9 were
measured using a Caspase-Glo Assay System (see Methods for details). The data are normalized to the luminescence signals for each caspase on
cells treated with DMSO (baseline). (n = 3; **p < 0.01)

(xenograft model). When the tumors reached a diameter
of ~5 mm, the mice were treated with gemcitabine
alone, SW IV-134 alone, or a combination of the two
cancer drugs. Mice treated with vehicle served as the
control group. While the individual drugs slowed the
tumor growth to a small degree (SW IV-134 > gemcitabine), combination therapy was substantially more effective (Fig. 5a, p < 0.0001). The median survival of mice
treated with combination therapy was 60 days as compared to 41, 46 and 52 days for the vehicle, gemcitabine
and SW IV-134 single-agent treatment groups, respectively (Fig. 5b, p = 0.02). Two out of 9 mice (22%) receiving combination therapy survived for more than 7

a

months, while no long-term survivors were observed
in all of the other groups. Long-term survivors are
highly unusual in xenograft models of pancreatic
cancer. With the exception of anticipated decreases in
WBC counts due to gemcitabine-associated side effects, we did not detect any other significant differences in laboratory parameters compared to the
control group (Additional file 1: Table S1 and Additional file 2: Table S2). Apart from mild peritonitis at
the site of the injection, organ analyses (brain, heart,
lungs, alimentary tract, kidneys, liver and pancreas)
did not reveal signs of adverse drug effects. We observed no abnormalities in mouse behavior (failure to

b
****p < 0.0001

*p = 0.02
****
*

Fig. 5 SW IV-134 augments gemcitabine in a mouse xenograft model of pancreatic cancer and improves survival. a Immunocompromised female
nude mice were injected in the right flank with 200 μL single cell suspension of 1 × 106 AsPC-1 cells (n = 9). Treatment started when tumors
reached ~5 mm in diameter. The mice received the following treatments by i.p. injection: SW IV-134 alone (daily 750 nmoles/100 μL), vehicle
(daily 100 μL as control), gemcitabine (weekly 3 mg/100 μL), and a combination of SW IV-134 (daily 750 nmoles/100 μL) and gemcitabine
(weekly 3 mg/100 μL). The tumors were measured every other day using digital calipers. Of note, at the end of the treatment interval (21 days), the tumors
of the mice receiving combination therapy were significantly smaller than the tumors of the other groups (p < 0.0001). b Kaplan-Meier survival curve of
mice in (a). The median survival of mice treated with combination therapy was 60 days as compared to 52, 41 and 46 days for the SW IV-134, vehicle and
gemcitabine groups, respectively (p = 0.02)
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groom or weight loss) and no drug related deaths in
our experiments.

Discussion
Pancreatic cancer has a poor prognosis and novel therapeutic approaches are desperately needed. Gemcitabine has
been combined safely with several other chemotherapeutics
in efforts to improve outcomes but success has been very
modest. For example, combination of gemcitabine with erlotinib or capecitabine mildly improved overall survival by
a few weeks [30, 31]. Recently, an intensive multi-drug
combination has shown more significant gains in survival.
The regimen includes doses of 5-FU, oxaliplatin, irinotecan,
and leucovorin (FOLFIRINOX). Overall survival improved
from 6.8 months to 11.1 months when gemcitabine was
added but at the cost of significant toxicity. FOLFIRINOX
was associated with substantially more adverse effects,
including febrile neutropenia, thrombocytopenia, diarrhea,
and sensory neuropathy [4]. As a consequence, this treatment option is only suitable for the healthiest of patients
suffering from pancreatic cancer.
Evading apoptosis is an important mechanism of
acquired or preexisting chemoresistance in pancreatic
cancer [32, 33]. Restoring the ability to undergo programmed cell death is therefore an attractive strategy
to enhance treatment efficiencies [34]. IAPs belong to a
family of proteins frequently involved in resistance of
pancreatic cancer to chemotherapeutics [28, 35]. XIAP
is the most prominent and potent member of this
family and its transcriptional down regulation or
pharmacologic blockade using SMAC mimetics has
been shown to sensitize pancreatic cancer cells to gemcitabine [11, 28]. Interestingly, depletion of cIAP-1 and
cIAP-2 alone was not sufficient to sensitize pancreatic
cancer cells to gemcitabine [17]. In agreement to these
earlier studies, we confirmed that decreased XIAP
levels substantially improved sensitivity to gemcitabine,
even in the context of residual XIAP expression (Fig. 1).
We therefore believe that this up-regulated cellular survival pathway represents an attractive target in patients
with pancreatic cancer. In order to exploit XIAP as a
putative pancreatic cancer target most efficiently, delivery
of its antagonist, the SMAC peptidomimetic, needs to be
rendered cancer selective, since a non-selective mimetic
would increase the risks for systemic toxicities. By
linking a SMAC mimetic to the sigma-2 ligand SV119,
we created a targeted therapeutic capable of delivering
its payload directly into the cancer cells [20, 22]. It is
important to note that SMAC mimetics, including our
targeted SW IV-134, induce cancer cell death via complex mechanisms, currently only incompletely elucidated. While XIAP is functionally blocked, cIAP-1/2 is
rapidly degraded, which leads to NIK-dependent TNFα
production and augmented target cell killing by

Page 8 of 10

inducing apoptosis [8, 20, 22]. Even though SW IV-134
targets the same pathways as SMAC itself, we found it
to be far more effective than the unconjugated SMAC
mimetic [20]. The reason(s) for its enhanced activity profile is not completely understood and constitutes an active
research area but we believe it is likely caused by an enhanced and cancer-selective uptake/internalization mechanism, as we have recently shown for the targeted
delivery of an erastin analog to treat pancreatic cancer
in vitro and in vivo [36].
This is the first description of using SW IV-134 in
combination with a standard chemotherapeutic, gemcitabine, in PDAC. However, it might achieve even better
treatment outcomes when combined with non-standard
experimental therapies, such as targeted TRAIL biologics [37]. In order to show the potential synergy between SW IV-134 and gemcitabine, we reduced the
doses of the individual drugs. We are currently in the
process of designing preclinical models of PDAC in
order to identify the maximum tolerated dose in vivo. At
the reduced doses, combination of SW IV-134 with
gemcitabine significantly slowed tumor growth and increased in the median overall survival of our animals.
Apart from a decrease in the WBC count, commonly
seen following gemcitabine chemotherapy [38], and mild
peritonitis at the site of injection, no toxicities were
observed.
Sigma-2 receptors are up-regulated in many cancer
types [39, 40] and SMAC mimetics have been shown
to sensitize many types of cancer to a wide array of
chemotherapeutic agents [17, 41, 42]. As a result, we
believe that SW IV-134 could potentially be used to
sensitize several additional sigma-2-expressing malignancies, including head and neck tumors, breast
cancer, lymphomas [43], and ovarian cancer [22] to
different chemotherapeutics. As such, the combination
therapy approach employed here may have implications beyond the treatment of patients with pancreatic
adenocarcinoma.

Conclusions
In this study, we described the ability of the sigma-2
receptor-targeted SMAC mimetic SW IV-134 to act as a
sensitizing agent for chemotherapy in a model of pancreatic cancer. This approach merits further investigation, since this cancer has been recalcitrant to most
standard therapies. This work is significant because
sigma-2 receptors are highly expressed in many types of
cancer. As a result, we believe that the targeted combination strategy will likely work for additional malignancies.
Since many chemotherapeutics, including SW IV-134, activate the intrinsic arm of the apoptotic pathway, it may
work well to accentuate the effects of a variety of
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therapeutics that trigger complementing effector arms of
programmed cell death, such as the TRAIL-induced extrinsic death pathway.

Additional files
Additional file 1: Table S1. Combined SW IV-134 and gemcitabine
therapy induces a moderate decrease in WBC count and has no effect on
the other CBC parameters in tumor-bearing mice. Complete blood count
(CBC) of immunocompromised nude mice treated daily with SW IV-134
and weekly gemcitabine for 3 weeks compared to vehicle (control). WBC
is reduced in the drug group, with mean = 2.4 compared to 4.7 in the
control group (p = 0.02). The differences in the rest of cell counts between
the two groups were not statistically significant. (PDF 75 kb)
Additional file 2: Table S2. Combined SW IV-134 and gemcitabine
therapy does not induce changes in serum chemistries in tumor-bearing
mice. Biochemical analysis of immunocompromised nude mice treated
daily with SW IV-134 and weekly gemcitabine for 3 weeks compared to
vehicle (control). The differences in laboratory values between the two
groups were not statistically significant. (PDF 16 kb)
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